IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S):

YEDGAR, Saul et

EXAMINER:

Not yet known

SERIAL NO.:

Not yet known

GROUP ART UNIT:

Not yet known

FILED:

Herewith

al.

Attorney Docket No.: P-2507-US1

FOR.:

USE OF LIPID CONJUGATES IN THE TREATMENT OF DISEASE

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§1.56, 1.97 and 1.98, this Information Disclosure Statement includes:

1. 🛛	Documents including patents, publications, and other information listed on the attached							
	Form PTO-1449 for consideration by the Examiner;							
2. 🔲	Form PTO-1449 which lists documents including patents, publications and other							
	nformation for consideration by the Examiner but in accordance with 37 C.F.R. 1.98(d)							
	loes not include those documents which have been previously cited or submitted to the							
	Patent Office in the following prior application U.S. Serial No, filed which is							
	properly identified and relied on.							
3. 🔲	Other information for the Examiner's consideration which was cited in a communication							
	from a foreign patent office in a counterpart foreign application.							

The information herein cited is only in fulfillment of Applicant(s) duty of candor in disclosing all information brought to Applicant(s) attention. This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art". If it should be determined that any of the

APPLICANTS: SERIAL NO.:

FILED: Page 2

YEDGAR, Saul et al.

listed documents do not constitute "prior art" under United States law, Applicant(s) reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicant(s) further reserve(s) the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

In accordance with MPEP Sections 609 and 707.05(b), it is requested that each and every document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing on Form PTO-1449. Such initialing is requested even if the Examiner does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application and is evidence that the Examiner has considered the document.

This Information Disclosure Statement is being filed:

I)	\bowtie	Within three (3) months of filing the subject Application or entry of the
subject	t Applio	cation into the national stage or before mailing of the first Office Action on
the me	rits whi	chever event occurs last pursuant to of 37 C.F.R §1.97 (b); or
П)		After the period specified in (I) but before the mailing date of either a final
Officia	al Actio	on under 37 C.F.R §1.113 or a notice of allowance under 37 C.F.R §1.311
which	ever occ	curs first;
*	1.	The undersigned hereby states that each item of information listed on
	the Fo	rm PTO-1449 was cited in a communication from a foreign Patent Office in a
	counte	erpart foreign application not more than three (3) months prior to the filing of
	this In	formation Disclosure Statement; or
	2.	the undersigned hereby authorizes the Patent Office to charge the fee
	in the	amount of \$180.00 under 37 C.F.R §1.17 (p) to Deposit Account 05-0649.
III)		After the period in (I) and (II) but before the payment of the issue fee,
	1.	The Undersigned hereby states:
		a)
		was cited in a communication from a foreign Patent Office in a counterpart

APPLICANTS: SERIAL NO.: FILED:

Page 3

YEDGAR, Saul et al.

foreign application not more than three (3) months prior to the filing of this Information Disclosure Statement; or

- 2. The Undersigned hereby authorizes the Patent Office to charge the Petition fee in the Amount of \$180.00 under 37 C.F.R §1.17 (p) to Deposit Account 05-0649.

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 05-0649.

Respectfully submitted

Mark S. Cohen

Attorney for Applicant(s) Registration No. 42,425

Dated: July 28, 2003

Eitan, Pearl, Latzer & Cohen Zedek, LLP.

10 Rockefeller Plaza, Suite 1001 New York, New York 10020

Tel: (212) 632-3480 Fax: (212) 632-3490

APPLICANTS: SERIAL NO.:

YEDGAR, Saul et al.

FILED: Page 2

listed documents do not constitute "prior art" under United States law, Applicant(s) reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicant(s) further reserve(s) the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

In accordance with MPEP Sections 609 and 707.05(b), it is requested that each and every document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing on Form PTO-1449. Such initialing is requested even if the Examiner does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application and is evidence that the Examiner has considered the document.

This Information Disclosure Statement is being filed:

Ŋ	\bowtie	Within	three	(3) months of f	iling the si	ubject Ap	plication (or entry of	the
subjec	t Appli	cation i	nto the	national stage o	r before ma	ailing of t	he first O	ffice Action	on
the me	rits whi	ichever	event o	ccurs last pursua	nt to of 37	C.F.R §1.9	97 (b); or		
II)		After 1	the peri	od specified in (I) but befor	e the mai	ling date o	of either a fi	inal
Officia	al Actic	n unde	r 37 C.	F.R §1.113 or a	notice of	allowance	under 37	C.F.R §1.3	311
which	ever oc	curs firs	st;		., .	•			
t .	1.		The ur	ndersigned herel	y states tha	t each iter	n of infor	nation listed	on
	the Fo	rm PTC)-1449 -	was cited in a co	mmunicatio	on from a	foreign Pa	tent Office i	in a
	counte	rpart fo	reign a	pplication not m	ore than thr	ree (3) mo	nths prior	to the filing	g of
	this In	formati	on Disc	losure Statement	; or				
	2.		the un	dersigned hereb	y authorizes	s the Pater	nt Office to	charge the	fee
	in the	amount	of \$180	0.00 under 37 C.	F.R §1.17 (p) to Depo	sit Accou	nt 05-0649.	
III)		After 1	the perio	od in (I) and (II)	but before	the payme	ent of the i	ssue fee,	
	1.	The U	Jndersig	gned hereby state	es:				
		a)		that each item	of informa	tion cited	on the fe	orm PTO-14	449
		was ci	ted in a	communication	from a fore	ign Patent	Office in	a counterpar	ιt

APPLICANTS: SERIAL NO.: FILED:

Page 3

YEDGAR, Saul et al.

foreign application not more than three (3) months prior to the filing of this Information Disclosure Statement; or

- 2. The Undersigned hereby authorizes the Patent Office to charge the Petition fee in the Amount of \$180.00 under 37 C.F.R §1.17 (p) to Deposit Account 05-0649.

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 05-0649.

Respectfully submitted,

Mark S. Cohen Attorney for Applicant(s) Registration No. 42,425

Dated: July 28, 2003

Eitan, Pearl, Latzer & Cohen Zedek, LLP. 10 Rockefeller Plaza, Suite 1001

New York, New York 10020

Tel: (212) 632-3480 Fax: (212) 632-3490 Approved for us through 10/31/99. OMB 0651-0031

Patent and Trad mark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

	Substitute	for form	1449A/PTO	Complete if Known			
				Application Number	Not yet Known		
INF	ORMA	TION	DISCLOSURE	Filing Date	Herewith		
STA	ATEME	NT B	Y APPLICANT	First Nam d Inventor	YEDGAR, Saul		
				Group Art Unit			
	use as ma	ny she	ets as necessary)	Examiner Name			
Sheet	1	of	2	Attorney Docket Number	P-2507-US1		

			U.S	S. PATENT DOCUMENTS		
Examiner nitials*	Cite No. 1	U.S. Patent Document Number Kind Code² (if known)		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA .	5,064,817		YEDGAR Shaul et al	Nov 12, 1991	
	AB	6,171,614		CHAIKOF Elliot L. et al.	Jan 9, 2001	
	AC .	6,162,787		SORGENTE Nino	Dec 19, 2000	
			 			
	4					•
<u></u>				- 17.		
		**	,			
			-			
	ļ		ļ			
· · · · · · · · · · · · · · · · · · ·						
	 	 	-	:		· · · · · · · · · · · · · · · · · · ·

	1. (1)			FORE	IGN PATENT DOCUM	ENTS	, , ,	
				Document	Name of Patentee or	Date of Publication of	Pages, Columns, Lines,	
Examiner Initials*	Cite No. 1	Office ³	Number ⁴	Kind Code ⁵ (if known)	Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T ⁶
		<u> -</u>			=			
	<u> </u>							
·								
				•				
	1							
	<u> </u>							
Examine Signatur					Dat . Cor	e nsidered		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁸ Applicant is to place a check mark here if English language Translation is attached.

Approv d for use through 10/31/99. OMB 0651-0031

Patent and Trad mark Office: U.S. DEPARTMENT OF COMMERCE

Und r the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

	Substit	ut for f	orm 1449B/PTO	Complete if Known			
				Application Number	Not yet known		
INF	ORMA	OITA	N DISCLOSURE	Filing Date	H rewith		
STA	ATEM	ENT I	BY APPLICANT	First Named Invent r	YEDGAR, Saul		
				Group Art Unit			
(use as n	nany sh	eets as necessary)	Examiner Name			
Sheet	2	of	2	Attorney Docket Number	P-2507-US1		

		NON	PATENT LITERATUR	RE DOCUMENTS						
Examiner Initials*	itials* No.1 publisher, city and/or country where published.									
	AD	stimulated P388D ₁ Ma	crophages; BALSINDE J	d Mobilization in Lipopolysa esus, BALBOA Maria A., Y Chemistry, Vol 275, Feb 18	EDGAR Saul, and					
	AE	conjugates achored to VAN ACKERN K, VA	the membrane BECK, G	ction in human lund end i. Ch, YARD B.A. SCHULT IMSKY M, KASZKIN M ar 4	E J., OBERACKER. R	,				
	AF.			hored extracellular inhibitory M and YEDGAR S.; FEB						
	Interaction of hyacluronic acid-linked phophatidylethonolmine (HyPE) with LDL and its effect on the susceptibility of LDL lips to oxidation; SCHNITZER Edit, DAGAN Arie, KRIMSKY Miron, LICHTENBERG Dov, PINCHUK Ilya, SHINAR Hadassa, YEDGAR Saul; CPL 104 (2000) 149-160									
	АН									
	-									
•			•							
2. 17		:		. , ,	• :					
. :			<u> </u>	<u> </u>						
: 1		1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	4.3 1	H 8 18						
Examir Signat		-:		Date Considered						

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw fine through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.